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Abstract
Background: Rheumatoid arthritis is a chronic inflammatory disease, which affects 1% of the population. Hands
and feet are most commonly involved followed by the cervical spine. The spinal column consists of vertebrae
stabilized by an intricate network of ligaments. Especially in the upper cervical spine, rheumatoid arthritis can
cause degeneration of these ligaments, causing laxity, instability and subluxation of the vertebral bodies.
Subsequent compression of the spinal cord and medulla oblongata can cause severe neurological deficits and even
sudden death. Once neurological deficits occur, progression is inevitable although the rapidity of progression is
highly variable. The first signs and symptoms are pain at the back of the head caused by compression of the major
occipital nerve, followed by loss of strength of arms and legs. The severity of the subluxation can be observed
with radiological investigations (MRI, CT) with a high sensitivity.
The authors have sent a Delphi Questionnaire about the current treatment strategies of craniocervical
involvement by rheumatoid arthritis to an international forum of expert rheumatologists and surgeons. The timing
of surgery in patients with radiographic instability without evidence of neurological deficit is an area of
considerable controversy. If signs and symptoms of myelopathy are present there is little chance of recovery to
normal levels after surgery.
Design: In this international multicenter randomized clinical trial, early surgical atlantoaxial fixation in patients
with rheumatoid arthritis and radiological abnormalities without neurological deficits will be compared with
prolonged conservative treatment. The main research question is whether early surgery can prevent radiological
and neurological progression. A cost-effectivity analysis will be performed. 250 patients are needed to answer the
research question.
Discussion: Early surgery could prevent serious neurological deficits, but may have peri-operative morbidity and
loss of rotation of the head and neck. The objective of this study is to identify the best timing of surgery for
patients at risk for the development of neurological signs and symptoms.
Published: 16 February 2006
BMC Musculoskeletal Disorders2006, 7:14 doi:10.1186/1471-2474-7-14
Received: 30 November 2005
Accepted: 16 February 2006
This article is available from: http://www.biomedcentral.com/1471-2474/7/14
© 2006Wolfs et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2006, 7:14 http://www.biomedcentral.com/1471-2474/7/14Background
Rheumatoid Arthritis (RA) is a chronic, systemic, inflam-
matory disease with an unknown etiology characterized
by an erosive synovitis. Genetic and environmental fac-
tors play an important role. Both humoral and cellular
immune responses are present. In caucasians the preva-
lence of RA is 0.8–1% [1] and the incidence is 27 per
100.000 of the general population [2]. The upper cervical
spine shows signs of damage in 17–86% of patients with
RA and is the most commonly involved structure after
hands and feet [3]. The huge difference in the prevalence
of cervical spine pathology is the result of absence of
standardized international accepted definitions of sublux-
ations of the atlantoaxial segment and inconsistent results
in the literature. The use of better anti-inflammatory drugs
in the last decade resulted in delayed and maybe a lower
incidence of cervical spine involvement.
The spinal column consists of vertebrae stabilized by an
intricate network of ligaments. Especially in the cervical
spine, rheumatoid arthritis can cause degeneration of
these ligaments, causing laxity, instability and subluxa-
tion of the vertebral bodies. Subsequent compression of
the spinal cord and medulla oblongata can cause severe
neurological deficits and even sudden death. Cervical
spine involvement typically begins early in the disease
process, and its progression has been closely correlated
with the extent of peripheral disease activity [4-6]. Several
types of subluxations have been described [3]. The first
signs and symptoms of atlantoaxial instability are the
result of rheumatoid synovial proliferation. Because of
erosions of the transverse, apical and alar ligaments an
anterior atlantoaxial subluxation (AAS) develops. Dam-
age to the transverse ligament alone will allow approxi-
mately 3 to 4 mm of subluxation; a greater anterior
atlanto dental interval (AADI) implies damage to the alar-
apical ligament complex, an incomplete odontoid peg or
a resorbed dens [4]. The average duration of RA at the
onset of AAS has been reported being 12.7 years (3–26
years) [7]. Many patients acquire AAS in the first 3 years of
their disease, but neurological impairments develop after
a mean period of 18 years (range 4–50 years) [8]. When
the odontoid process erodes a posterior AAS can evolve.
Vertical Translocation (VT) (Cranial settling, basilar
invagination, or superior migration of the odontoid proc-
ess) results from progressive destruction of the lateral
mass joints (atlantoaxial and occipitoatlantal) and the lat-
eral masses themselves, as a result of chronic craniocervi-
cal instability [9-11]. The odontoid process moves
towards and beyond the borders of the foramen magnum.
Secondarily periodontoid pannus is formed in reaction to
the chronic instability [3,12]. VT is observed in 4–35% of
patients [13]. Because of VT the AADI can decrease, which
virtually is a paradoxal improvement [9,14,15]. VT
appears after a mean of 16.5 years (4–33 years) after the
onset of the RA inflammatory process and almost exclu-
sively after the onset of AAS [8,16]. Involvement of the
subaxial spine (SAS) is less common, occurs later in the
course of the disease, and manifests as multilevel anterior
dislocation (7–29%) [13].
Signs and symptoms
Clinical signs and symptoms as a result of AAS vary from
asymptomatic to total incapacitation. Occipital pain, both
from joint destruction and occipital nerve entrapment,
and signs and symptoms of myelopathy are the most
common complaints. Symptoms caused by instability are
neck pain, headache and occipital neuralgia. As a result of
medullary compression paresthesias, numbness, weak-
ness, jactitations and sphincter disturbances can develop.
When VT is present with medullary compression the signs
and symptoms can be dysarthia, dysphonia, dysphagia,
diplopia, facial numbness (cranial nerve palsies), sleep
apnea, and long tract signs. The long tract signs are diffi-
cult to assess, since the disability caused by progressive
joint disease can obscure objective long tract signs such as
hyperreflexia and spasticity. Severe compression of the
medulla oblongata can result in vascular insufficiency
leading to dizziness, vertigo and syncope. Vertebrobasilar
ischemia is rare and occurs as a result of compression by
the odontoid process [17,18]. VT can also give rise to cru-
ciate paralysis and occasionally sudden death. The pres-
ence of symptoms is not correlated with the severity of
radiological abnormalities.
Natural history
The time interval between the existence of AAS and the
development of neurological signs and symptoms varies
widely [16,19-24]. A review by Bouchaud-Chabot [3]
showed that at least 15% of the patients with radiological
subluxation had no symptoms or signs. Progressive neu-
rological deficits have been reported to be present in 15 to
36% of patients with RA [13]. If neurological deficits
occur, spontaneous recovery can not be expected with
conservative treatment and progression is inevitable and
portends a poor prognosis [6,25-29]. About 50% of these
patients die within 6 months and almost everyone dies
within a few years after the first signs of myelopathy
[2,25].
Treatment
Generally accepted indications for atlantoaxial surgical
fixation are severe C2 neuralgia and neurological deficits
(Ranawat IIIA and IIIB) with signs and symptoms of mye-
lopathy [13,14,16,30]. Surgical intervention is indicated
to reduce and stabilize the craniocervical junction, pre-
serve or restore neurological function and prevent further
neurological deterioration [1,2,9,31-33]. However, there
is no consensus or guideline when to operate on asymp-Page 2 of 12
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surgeons and rheumatologists prefer to operate in an early
stage of the disease [34], others operate once neurological
signs and symptoms have occurred [14]. Surgery in
patients without neurological deficits is easier and less
complex compared to patients with neurological impair-
ments [9,32,34-36]. On the other hand loss of rotation
occurs and there is a small risk of morbidity.
As a result of lack of evidence of the beneficial effect of
surgery in an early stage of the disease, not all rheumatol-
ogists screen routinely for AAS as a result of the RA. Some
rheumatologists screen patients with plain radiographs,
others perform radiological investigations once patients
present with complaints or neurological deficits.
Until the early 90's, the classical surgical approaches had
a very high peri-operative morbidity and mortality rate.
Since 1996, new surgical techniques with titanium instru-
mentation are used that are safer and make it possible to
mobilize patients the first day after surgery [37-42]. In a
study performed by Agarwal [7] no VT appeared after
'early' atlantoaxial fixation in patients with anterior AAS.
Adjacent level involvement after occipitocervical fixation
is approximately 7% in 3 years [43], this percentage is
lower if only a C1C2 fixation has been performed.
The mortality rate of patients with myelopathy treated
conservatively is very high. However, non ambulant quad-
riparetic patients who were operated on had a poor prog-
nosis as well [2,9,27]. In a study performed by Casey and
Crockard, the mortality rate of operated Ranawat IIIB
patients was 58% within 3 years, compared to 20% of
Ranawat IIIA patients [2]. The Class IIIB patients have
unique management considerations in which surgery
(despite high morbidity) often remains the best therapeu-
tic option available. Improvement of even one grade in
their Ranawat score from Class IIIB to Class IIIA brought
about by surgery confers on them a huge benefit in terms
of their quality of life and survival [9].
The Delphi Trial – I(RCT)2
What is lacking from the literature is a prospective, rheu-
matoid population based study that gives information
about the prevalence and progression of AAS, VT, or other
important manifestations of RA involvement of the cervi-
cal spine. Because of the variable time interval between
the existence of radiological atlantoaxial cervical spine
involvement and the development of neurological defi-
cits, it is not known when surgical fixation has to be per-
formed. In the literature many authors suggest that a
randomized clinical trial about the best timing of surgery
in AAS as a result of RA has to be performed
[1,2,9,11,34,43]. The objective of this study is to compare
early surgery with prolonged conservative treatment for
patients with rheumatoid arthritis and atlantoaxial cervi-
cal spine involvement without neurological impairments.
Design
An international multicenter randomized clinical trial
will be performed. Centers in the Netherlands (table 1),
Belgium, Denmark, France, Germany, Italy, Latvia, Portu-
Table 1: Dutch rheumatological centers participating in the delphi trial.
Rheumatological centers The Netherlands
Atrium MC Heerlen Heerlen Houben
Delfzicht Delfzijl Mertens
Goes Oosterschelde Ziekenhuis Goes Sonaville
Haarlem Gasthuis Haarlem Linssen
Isala Klinieken Zwolle Zwolle Kuiper, v Veen, Zijlstra
Jan van Breemen Instituut Amsterdam Dinant
Jeroen Bosch Ziekenhuis Den Bosch v Oijen, Haverman, Hartkamp
Leiden University Medical Center Leiden Huizinga, Kloppenburg, Breedveld, Laar
St Maartenskliniek Nijmegen Nijmegen Bosch, Rooij
MCH Haaglanden Den Haag Collee
Medisch Centrum Maastricht Maastricht Vosse
Medisch Centrum Leeuwarden Leeuwarden Griep, Jansen
Reinier De Graaf Delft Peeters
Slotervaart Ziekenhuis Amsterdam Lens
St Franciscus gasthuis Rotterdam Rotterdam Paassen;
St Franciscus Roozendaal Roozendaal Seys, Groenendaal
Streek Ziekenhuis Hengelo Hengelo Bernelot
Twee steden Ziekenhuis Tilburg Brus
UMC St Radbout Nijmegen Nijmegen Vd Koojen, Heereveld
VU Medical Center Amsterdam Amsterdam Boers, Dijkmans, Brouwer
University Medical Center Utrecht Utrecht BijlsmaPage 3 of 12
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and Canada will participate (table 2 and figure 1 and 2).
The multicenter design is necessary to recruit all patients
in the inclusion period of 2 years. Early surgery will be
compared with prolonged conservative treatment. The
selection and randomization procedure is depicted in fig-
ure 3. The overall range for randomization of the AAS is
an AADI between 5–12 mm. Participating centers/coun-
tries are allowed to randomize different intervals of sub-
luxation. The intervals are predefined as 5–8 mm, 5–12
mm and 8–12 mm. Demographic and clinical data will be
collected of each patient. The randomization of all
patients will be performed centrally at the LUMC by the
trial coordinator and datamanager by a concealed rand-
omization list in random permuted blocks.
After a follow up of 5 years the main research question
will be answered, although the total follow-up will be 10
years. Patients excluded from the trial will be followed in
a cohort group and treated according to the usual care by
surgical fixation or conservative treatment. The LUMC will
function as the research and data coordinating center,
where the data will be collected, analyzed and publica-
tions prepared. Eligibility criteria will differ from site to
site, according to local perceptions of equipoise. These
efforts will increase the generalization of the results. The
authors have full access to the data, direct the data-analy-
sis and are responsible for decisions regarding publica-
tion. The principal investigator and the trial coordinator
assume full responsibility for the integrity and interpreta-
tion of the data.
Main research questions
Null hypothesis; there is no difference in outcome
between early surgical fixation and prolonged conserva-
tive treatment in patients with AAS with an AADI between
Table 2: All international participating surgical (orthopedic and neurosurgical) centers throughout the world.
Surgical Centers
Country Surgeon Center
The Netherlands Peul LUMC
Pavlov St Maartenskliniek Nijmegen
Pöll Slotervaart Amsterdam/VUMC/JBI
Santbrinck AMC Maastricht
Coppes AZG Groningen
De Beer Isala Klinieken Zwolle
Belgium Lauwerijns Catholic University Hospital, Leuven
Denmark Bünger University Hospital of Aarhus
Kruse University Hospital Copenhagen
Finland Mäkelä Oulu University Hospital
France Vital Tripode Hospital, Bordeaux
Bancel Alleroy-Labrouste Paris
Germany Kothe University Hospital Hamburg-Eppendorf
Bünger University Hospital Aarhus
Italy Parisini Institute of Orthopedics Rizzoli, Bologna
Visocchi Catholic University, Rome
Latvia Vestermanis Pauls Stradins Clinical University Hospital, Riga
Portugal Pereira/Vaz Hospital S. Joao, Porto
Spain Secundino Hospital Trueta, Girona
Sweden Hedlund Karolinska Stockholm
Olerud Uppsala University Hospital, Uppsala
Vavruch Ryhov Hospital, Ryhov
Switzerland Grob Schultess Klinik Zurich
Jeanneret University of Basel Medical School, Basel
Schizas, Duff CHUV, Lausanne
Turkey Zileli Ege University
United Kingdom Casey Queen Square London
Timothy/Towns Leeds General Infirmary
USA Hilibrand Thomas Jefferson University, Philadelphia
Wang UCLA Spine Center, Santa Monica
Carlson St. Josephs Hospital Orange Irvine
Canada Fehlings Toronto Western Hospital, Toronto
Dvorak Vancouver General HospitalPage 4 of 12
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of the many uncertainties in the rheumatoid arthritis
process the following research questions will be answered.
1. Does early surgery in neurological intact patients with
RA and radiological signs of AAS result in less progression
of C1–C2 subluxation and VT with or without complaints
and neurological disability compared to prolonged con-
servative treatment?
2. Is early surgery more cost-effective than prolonged con-
servative treatment in this patient population?
European participating centers in the delphi trialFigur  1
European participating centers in the delphi trial.Page 5 of 12
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answered.
3. Is it possible to define subgroups, which benefit most
from one of the allocated treatment strategies?
Patients
All patients with RA and atlantoaxial cervical spine
involvement on conventional X-rays, CT or MRI of the cer-
vical spine without neurological impairments will be
asked to participate in the trial at one of the participating
RA specialized hospitals. If patients with RA, aged 18–70
years old, have an AAS in the randomization range with-
out neurological impairments (Ranawat I and II) without
severe comorbidity, MRI incompatibility or previous cer-
vical surgery, early surgical fixation will be compared with
prolonged conservative treatment. The in- and exclusion
criteria of the delphi trial are listed in table 3. Patients with
neurological deficits as a result of cervical spine involve-
ment will be followed in a cohort group.
Sample size/power calculation
The sample size is calculated on the basis of the outcome
difference during the follow-up period of at least 5 years.
Hypothetically, 8% of included patients will worsen in
the 5 year follow up period resulting in an event (Kaplan
Meier) (16,21). In the early surgery group the event rate is
expected to be 2% or less [44]. 2% is chosen because it has
to be a save alternative to 'wait and see'. A two-sided log
rank test with an overall sample size of 250 patients,
achieves 90% power at a 0.05 significance level to detect a
difference in groups 1 and 2 after 5 years of follow up.
Patients enter the study during an accrual period of 2
years. 50% of the enrolment is complete when 50% of the
accrual time has past. A follow-up period of 5 years with a
20% loss from group 1 and a 20% loss from group 2 is cal-
culated.
Interventions
Surgical treatment
Different surgical opportunities and techniques for cervi-
cal fixation exist. The choice of technique depends on the
severity of the cervical spine involvement and the sur-
geon's preference. Surgery will be performed according to
local standards and to the discretion of the surgeons, but
a standardized minimal surgical technique is required. All
approved cervical spine fixation systems are allowed in
this trial. If AAS is present a C1–C2 screw fixation accord-
ing to Magerl or Harms with or without wiring tech-
niques, or a Hook C1–C2 fixation will be performed.
When VT has occured, the cranium will be fixated to the
upper cervical spine with fixation to the C1–C2 screws.
For each patient, the surgeons will register which tech-
nique they have used.
Conservative treatment
Conservative treatment consists of antirheumatoid drugs
(i.e, NSAID, DMARD, biologicals). The choice of drugs is
Participating centers from the United States of America and Canada in the Delphi trialFigure 2
Participating centers from the United States of America and Canada in the Delphi trial.Page 6 of 12
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progressive neurological deficits, progressive radiological
abnormalities, and intolerable pain represent a failure of
conservative management and are an indication for surgi-
cal fixation.
Cohort study
Many patients with rheumatoid arthritis do have cervical
spine involvement but only a small proportion of these
patients will be eligible for randomization. All patients
with RA and AAS excluded for the randomization group
will be offered to be followed in a separate cohort study
design. The inclusion and exclusion criteria are only
important for the group of patients that will be rand-
omized and not for patients in the cohort group. Criteria
for the cohort group are shown in table 4. Patients with an
AADI less than 5 mm will be treated conservatively until
the AADI enlarges. Patients with an AADI larger than 12
mm will be offered surgery. A follow up with X-rays and
MRI scans of the cervical spine will be performed at prede-
fined time intervals. The neurological and radiological
outcome and quality of life will be analyzed.
Primary and secondary outcome parameters
The primary outcome is the occurrence of an event. Events
are defined as 1) neurological deficit, 2) radiological pro-
gression, 3) surgery, 4) resurgery, 5) death. (see table 5).
1). Neurological deficit is defined as a worsening in the
Ranawat scale to IIIA or IIIB, or a deterioration of the MDI
The recruitment and selection of patients for the randomization procedure of the Delphi trial is shownFigu e 3
The recruitment and selection of patients for the randomization procedure of the Delphi trial is shown.
Table 3: In- and exclusion criteria for the randomization procedure of the delphi trial.
Inclusion Criteria Exclusion Criteria
• Rheumatoid Arthritis patients • Ranawat IIIA and IIIB: neurological impairment
• Age 18–70 • Severe comorbidity
• Ranawat I and II: no neurological impairment • Previous cervical surgery
• C1–C2 subluxation: • C1–C2 subluxation: AADI smaller or larger than the randomization 
range
AADI: 5–8 mm
AADI: 5–12 mm
AADI: 8–12 mm
• C1–C2 subluxation reducible or irreducible • MRI incompatibility
• Informed consentPage 7 of 12
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ical classification and useful in evaluating patients, plan-
ning treatment and evaluating results. Class I patients
have no neurological deficit, Class II patients have subjec-
tive weakness with hyperreflexia and dysesthesia. Class
IIIA patients have objective weakness and long tract signs.
Class IIIB patients are wheelchair bound or bedridden.
The Ranawat classification fails to differentiate reliably
between classes II and IIIA, the area of most clinical inter-
est to the operating surgeon [45]. Casey and Crockard
developed and validated the MDI according to the Stan-
ford HAQ. The MDI consists of 10 functional questions.
The more severe a patient has been disabled the higher the
score [45].
2). Radiological progression is defined as an enlarged
AADI of more than 12 mm, development of VT with
impingement of the spinal cord or medulla oblongata, or
signs of myelopathy. The Redlund Johnell method will be
used to measure the severity of VT, which is the distance
of the base of C2 to the palato-occipital line of McGregor
(less than 34 mm in men and 29 mm in women) [11].
3). Incidence of surgery in the conservative treatment
group. One of the goals of the conservative treatment is to
avoid surgery for intolerable pain for example. The surgi-
cal rate is therefore an indication of the success or failure
of the conservative treatment policy.
4). The incidence of resurgery at the cervical spine in the
early surgery group will be an indication of the failure rate
for surgery.
5). Death: all causes.
Secondary outcome parameters
1) 'Perceived recovery/deterioration.' This is a seven-point
Likert scale measuring the perceived recovery or progres-
sion, varying from 'completely recovered' to 'worse than
ever'.
2). The American Spinal Injury Association (ASIA) and
International Medical Society of Paraplegia have devel-
oped a standard form for capturing clinical information
when evaluating a patient who has had a spinal cord
injury. The ASIA score is a motor and sensory quantifying
score of both arms and legs [46]. The ASIA score will be
used once neurological deficits have occurred.
3). The Disease Activity Score (DAS-28) is a classification
used by many rheumatologists and is a measure of the
overall disease activity of RA. In Europe the DAS is the rec-
ognized standard in research and clinical practice. For a
good comparison of the severity and disability due to the
RA inflammatory process between all patients in the two
treatment groups of the different countries the DAS-28
will be used. The following parameters are included in the
calculation: Number of joints tender to touch (TEN),
Number of swollen joints (SW), Erythrocyte sedimenta-
tion rate (ESR), patient assessment of disease activity [47].
4). VAS pain will be measured of pain in the neck and
occiput before randomization and during the follow up.
Pain will be assessed on a horizontal 100 mm scale vary-
ing from 0 mm, 'no pain', to 100 mm, 'the worst pain ever'
[48].
5) EuroQol classification system and VAS rating personal
health [49]. A cost-utility analysis will be performed using
QALY's based on the EuroQol questionnaire, which has
been validated in many studies and is easy to fill out.
Patients describe their general health status using the
Table 4: Eligibility criteria for the cohort group.
Cohort Group
1. Ranawat III A
2. Ranawat III B
3. Too strong preference
Conservative treatment
Surgical treatment
4. AADI < 5 mm: conservative treatment preferential
5. AADI > 12 mm: surgical treatment preferential
6. Exclusion because of in and exclusion criteria
Table 5: Primary outcome parameters: Events
Event
1. Neurological disability Worsened MDI > 3 points
Signs of myelopathy (Ranawat IIIA and IIIB)
2. Radiological progression Signs of myelopathy on MRI
Vertical translocation/Impression brainstem AADI > 12 mm
3. Surgery Conservative treatment group
- Intolerable pain
4. Resurgery Surgical group
5. Death All causesPage 8 of 12
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on mobility, self care, usual activities, pain/discomfort,
and anxiety/depression. Patients also rate their personal
health using a visual analogue scale (VAS) ranging from
worst imaginable health to best imaginable health.
6) Short-Form 36 (SF-36). Quality of life will also be
assessed using the RAND-36 questionnaire [50]. This is a
generic health status questionnaire, which can easily be
filled out at home. The questionnaire consists of 36 items
on physical and social functioning.
7) Imaging findings. The results of the differences
between the baseline X-ray, MRI and CT scan and those
investigations during the follow up after randomization
are important secondary outcome measures. The differ-
ence in AADI, PADI, Redlund-Johnell (VT), signs of mye-
lopathy or compression, subaxial involvement, amount
of pannus tissue and signs of fusion will be registered.
Failures of surgery can be recognized by screw breakage,
progression of AAS or VT.
Database
All data collected of patients participating in this trial are
registered in a database under the ProMISe data manage-
ment system of the Department of Medical Statistics of the
LUMC. Database access is secure and limited to the trial
coordinator, the trial data manager and the principal stat-
istician. At patient enrollment into the trial, a unique
study identification number is issued. The database will
not contain any information directly identifying the study
subject. However, to avoid errors during data collection in
the follow-up of the patient, the patient's initials (first
character of first name and first character of last name)
will be entered as well as the gender and date of birth of
the patient. The local hospital number of the patient is
also part of the registration. The investigator in each par-
ticipating hospital will maintain a list in which the corre-
spondence between the true identity of the subject and its
study number is documented. Follow-up data sent from
each participating hospital to the central data manage-
ment will only contain the study ID of the subject but not
any data directly revealing the identity of the subject. It is
the responsibility of each local hospital research coordi-
nator to ensure the integrity of the correspondence
between the Study ID and the true identity of the patient.
The data manager will enter follow up data and verify that
the date of birth of the follow up data forms is identical to
the date of birth on the entry form. Discrepancies are to be
solved by the local coordinator. This system ensures that
only a local physician can infer the identity of any partic-
ipating subject.
Follow up
Follow up with clinical assessments and outcome meas-
ures will be assessed at baseline and after 3, 6, 12, 18 and
24 months. After two years the patient will be controlled
once a year till eventually 10 years after randomization.
During the follow up parameters will be registered to eval-
uate the quality of life, illness restrictions and neurologi-
cal impairments. Direct and indirect medical costs will be
calculated in each group.
Every control moment an X-ray of the cervical spine will
be made (neutral/flexion/deflexion) except three months
postoperatively. Prior to randomization and six months
postoperatively a CT scan will be made to evaluate fusion
and surgical stabilization. At fixed intervals and on clini-
cal indication a MRI scan of the cervical spine will be per-
formed. The clinical, neurological and radiological
parameters will be registered on the follow up CRF. Data
collection will take place per treatment center and will be
gathered and analyzed at the LUMC in Leiden by the trial
coordinator together with the statistical department and
the epidemiological department of the VUMC in Amster-
dam.
Statistical analysis
The researchers will be aware of allocation to early surgery
or conservative treatment at the time of the statistical anal-
yses. There will be an intermediate analysis after 2 years of
follow up. The intermediate outcome measures are pro-
gression of AAS and VT with or without (pain) complaints
and neurological disability (measured with the MDI and
Ranawat). The main analyses will be performed after 5
years and 10 years of follow up. At these intervals the pri-
mary outcome parameter is the occurrence of an event as
described in table 5. Baseline comparability will be inves-
tigated by descriptive statistics to examine if randomiza-
tion was successful. Differences in success rates between
both groups are calculated, together with 95 percent con-
fidence intervals. In addition to an analysis of the differ-
ence in outcome between the two groups analyses of the
difference in time to progression will be carried out. Con-
tinuous outcomes are evaluated as change scores (differ-
ences between baseline measurement and each follow-up
measurement). Multivariable analyses are performed to
adjust for the eventual differences between the groups at
baseline in prognostic indicators. All the analyses are per-
formed according to the intention-to-treat principle. An
additional per protocol analysis will be performed com-
paring patients in the conservative group who received
surgery with patients in the same group who had not and
with patients in the surgery group. To compare the actual
treatment sec instead of strategies an explorative analysis
will be performed in subgroups of all patients who actu-
ally received surgery and who did not receive surgery inPage 9 of 12
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included in the analysis until the time of withdrawal.
To answer the third research question, explorative analy-
ses are conducted to investigate whether the treatment
effect varies in specific subgroups of patients. Using logis-
tic regression for success rate and linear regression for
severity of the disability, each prognostic indicator is
checked for interaction with treatment.
Economic evaluation
The result of this study is based on both the short-term
and long-term success of surgical intervention and pro-
longed conservative treatment. The economic evaluation
will be performed from a societal perspective. Both health
care costs and costs of production losses will be included.
Health care costs will include costs of general practice
care, medical specialist care, physiotherapy, hospitalisa-
tion, medication and other costs directly associated with
diagnosis, treatment and rehabilitation.
There are many variable parameters influencing the total
costs of the surgical fixation (surgery time, extend of sur-
gical fixation, systems used), which makes it very difficult
to calculate the real costs of the surgical procedure. There-
fore, real costs of surgery will not be estimated but based
on standard prices in the participating hospitals. The costs
of hospital admission in the surgical group will be calcu-
lated by the days spent on the Intensive Care Unit and the
surgical department. Side-effects and complications
related to the treatment are recorded by the patients, the
treating surgeon or rheumatologist. The costs of complica-
tions will be reflected in additional intervention, pro-
longed duration of ICU stay and total admission time. The
costs for re-surgery in the early surgery group and surgery
in the conservative group will also be estimated.
In the study MRI and CT scans will be performed in both
treatment groups. The costs of these imaging techniques
will be included. The costs of the CT scan will only be cal-
culated for patients undergoing surgery, because in the
normal situation, CT would only be performed if a surgi-
cal indication exists. CT scans that are only used for
research purposes will not be included.
Patients will register other health care needs in a diary
(including physiotherapy, visits to GP's and specialists,
nursing care and medication). Each diary covers a period
of 3 months. The costs of health care will be assessed
using standard prices. Patient/family costs and costs of
production losses will also be collected in the cost diaries.
Cost-effectiveness and cost-utility analysis
The aim of the economic evaluation will be to determine
and compare the total costs for patients receiving surgery
or conservative care, and to relate these costs to the effects
of the interventions. The economic evaluation will be
conducted from societal perspective and will be carried
out according to the intention-to-treat principle. Boot-
strapping will be used for pair-wise comparison of the
mean differences in total costs between the intervention
groups. Confidence intervals will be obtained by bias cor-
rected and accelerated (Bca) bootstrapping using 2000
replications.
Cost-effectiveness ratios will be calculated by dividing the
difference in mean costs of the two interventions by the
difference in mean effects of the two interventions. Ratios
will include the primary clinical effect measures of the
trial. Cost-utility ratios will also be calculated. Ratios will
be graphically presented on cost-effectiveness and cost-
utility planes. Acceptability curves will also be presented.
Discussion
Ethical considerations
Is it fair to perform a surgical cervical fixation on patients
with rheumatoid arthritis with atlantoaxial pathology
without neurological complaints? From the literature it is
not known which treatment is preferable. Advantages of
early surgery are probable preservation of neurological
functions with a higher degree of general functioning. The
surgical fixation will be less extensive and easier to per-
form compared to surgery in a later stage, because of the
more pronounced destruction of the joints and bones. If
neurological deficits are present before surgical fixation,
there is little chance of (full) neurological recovery. The
large variability in the progression of AAS, eventually
resulting in neurological deficits, makes it hard to deter-
mine the right timing for surgical fixation. It can take years
before patients get neurological complaints or deficits.
Another disadvantage is that with surgery in an earlier
phase of AAS more patients have to be operated on. After
surgical fixation, patients are more restricted in their head
and neck movements. In turn, it must be noted that lim-
ited neck range of motion already exists in 90% of patients
with RA. The overall conclusion is that it is fair to practice
surgical fixation before the onset of neurological signs and
symptoms in patients with significant AAS.
List of abbreviation
AAS: Atlanto Axial Subluxation
ASIA: American Spinal Injury Association
AADI: Anterior Atlanto Dental Interval
CT: Computer Tomography
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MDI: Myelopathy Disability Index
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PADI: Posterior Atlanto Dental Interval
RA: Rheumatoid Arthritis
SF-36: Short Form 36
SAS: Subaxial Subluxation
VAS: Visual Analogue Scale
VT: Vertical Translocation
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